CYD四价登革热疫苗在既往感染者的单型与多型免疫背景下的效果
基于两项随机安慰剂对照3期试验的免疫原性亚组,按基线登革热PRNT结果将既往感染者分为单型或多型免疫,评估CYD-TDV对症状性VCD和住院VCD的疫苗效力。结果显示单型与多型免疫者均有获益,单型免疫者绝对风险降低更大。
要点
- 单型免疫者症状性VCD的VE为77.4%,多型免疫者为89.2%。
- 单型免疫者住院VCD的VE为75.3%,多型免疫者为81.2%。
- 单型免疫者绝对风险降低更大,公共卫生获益更显著。
核心结论
- CYD-TDV对单型免疫和多型免疫的既往登革热感染者均有保护作用。
- 单型免疫者绝对风险降低更大,预期公共卫生获益更大。
研究设计与样本
- 两项随机安慰剂对照3期试验(CYD14、CYD15)的免疫原性亚组分析,共3927名参与者。
- 按基线登革热PRNT结果分为单型或多型免疫,评估25个月症状性VCD和6年住院VCD的疫苗效力。
主要发现
- 单型免疫组疫苗组496例、安慰剂组257例;多型免疫组疫苗组1227例、安慰剂组612例。
- 症状性VCD的VE:单型77.4%(95% CI 56.4%-88.2%),多型89.2%(95% CI 71.5%-95.9%)。
- 住院VCD的VE:单型75.3%(95% CI 42.7%-90.2%),多型81.2%(95% CI 21.7%-96.8%)。
临床怎么用
- 对既往登革热感染者接种CYD-TDV可降低症状性和住院VCD风险。
- 单型免疫者绝对风险降低更大,应优先考虑接种以获取更大公共卫生收益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immune profile of dengue-experienced individuals is a determinant of dengue reinfection severity risk. Individuals with a single prior dengue infection (monotypic) are at highest risk for severe disease, while individuals with ≥ 2 prior dengue infections (multitypic) are at lower risk. The tetravalent dengue vaccine (CYD-TDV) has shown efficacy in the prevention of dengue in individuals with prior dengue infection. We estimated efficacy in individuals with monotypic or multitypic immune profiles. METHODS: Participants enrolled in the immunogenicity subsets of 2 randomized placebo-controlled phase 3 studies (CYD14, NCT01373281; CYD15, NCT01374516) were classified as either monotypic or multitypic, based on measured baseline dengue plaque reduction neutralization test. Vaccine efficacy (VE) against symptomatic virologically confirmed dengue (VCD) was assessed over 25 months and against VCD hospitalization over 6 years. RESULTS: Of 3927 participants in the immunogenicity subsets, 496 and 257 in the CYD-TDV and placebo groups, respectively, were classified as monotypic immune, and 1227 and 612, respectively, as multitypic immune. VE against symptomatic VCD was 77.4% (95% CI, 56.4%-88.2%) for monotypic and 89.2% (95% CI, 71.5%-95.9%) for multitypic profiles, with corresponding absolute risk reductions (ARRs) of 4.48% (95% CI, 2.32%-6.65%) for monotypics and 1.67% (95% CI, .89%-2.46%) for multitypics. VE against hospitalized VCD was 75.3% (95% CI, 42.7%-90.2%) in monotypics and 81.2% (95% CI, 21.7%-96.8%) in multitypics, with ARRs of 0.95% (95% CI, .37%-1.53%) for monotypics and 0.18% (95% CI, .02%-.34%) for multitypics. CONCLUSIONS: CYD-TDV benefits individuals with monotypic and multitypic immune profiles. Larger public health benefit is expected to derive from the protection of individuals with a monotypic immune profile.
引用
- DiazGranados CA, Langevin E, Bonaparte M, et al. CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals. Clin Infect Dis. 2021. PMID: 32198515. doi:10.1093/cid/ciaa304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。